biostudies-literatureUnknown10(2)Dai ZJ<h4>Background</h4>Multiagent chemotherapy is the primary treatment for acute lymphoblastic leukemia (ALL), of which asparaginases including <i>Escherichia coli</i> L-asparaginase (<i>E. coli</i> L-Asp) and pegylated-asparaginase (PEG-Asp), are cornerstone components. The study aimed to conduct a meta-analysis to compare the efficacy and safety of PEG-Asp with <i>E. coli</i> L-Asp in Chinese children with ALL.<h4>Methods</h4>A systematic literature search was conducted to collect randomized controlled trials (RCTs) on PEG-Asp versus <i>E. coli</i> L-Asp in Chinese children with ALL. Two reviewers independently selected articles and extracted data. Risk-of-bias assessment was conducted with Cochrane recommendation tool. Pooled estimates and risk ratios (RRs) with 95% confidence intervals (CTranslational pediatrics244-255https://www.ebi.ac.uk/biostudies/studies/S-EPMC7944179biostudies-literatureEfficacy and safety of PEG-asparaginase versus <i>E. coli</i> L-asparaginase in Chinese children with acute lymphoblastic leukemia: a meta-analysis.PMC7944179Dai ZJLu YHuang YQfalseEfficacy and safety of PEG-asparaginase versus <i>E. coli</i> L-asparaginase in Chinese children with acute lymphoblastic leukemia: a meta-analysis.<h4>Background</h4>Multiagent chemotherapy is the primary treatment for acute lymphoblastic leukemia (ALL), of which asparaginases including <i>Escherichia coli</i> L-asparaginase (<i>E. coli</i> L-Asp) and pegylated-asparaginase (PEG-Asp), are cornerstone components. The study aimed to conduct a meta-analysis to compare the efficacy and safety of PEG-Asp with <i>E. coli</i> L-Asp in Chinese children with ALL.<h4>Methods</h4>A systematic literature search was conducted to collect randomized controlled trials (RCTs) on PEG-Asp versus <i>E. coli</i> L-Asp in Chinese children with ALL. Two reviewers independently selected articles and extracted data. Risk-of-bias assessment was conducted with Cochrane recommendation tool. Pooled estimates and risk ratios (RRs) with 95% confidence intervals (C2021-01-01T00:00:00Z2021 Feb2025-04-26T18:23:53.245Z2025-02-19T01:40:11.267ZS-EPMC79441793370851010.21037/tp-20-178